Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States

Author:

Rencsok Emily M.12ORCID,Slopen Natalie3ORCID,McManus Hannah D.4ORCID,Autio Karen A.5ORCID,Morgans Alicia K.6ORCID,McSwain Lawrence7,Barata Pedro89ORCID,Cheng Heather H.1011ORCID,Dreicer Robert12ORCID,Gerke Travis13ORCID,Green Rebecca13ORCID,Heath Elisabeth I.14ORCID,Howard Lauren E.4ORCID,McKay Rana R.15ORCID,Nowak Joel716ORCID,Pileggi Shannon13ORCID,Pomerantz Mark M.6ORCID,Rathkopf Dana E.5ORCID,Tagawa Scott T.17ORCID,Whang Young E.18ORCID,Ragin Camille1920ORCID,Odedina Folakemi T.2122ORCID,Kantoff Philip W.523ORCID,Vinson Jake13ORCID,Villanti Paul24ORCID,Haneuse Sebastien25ORCID,Mucci Lorelei A.1ORCID,George Daniel J.4ORCID,

Affiliation:

1. 1Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.

2. 2Harvard-MIT Division of Health Sciences and Technology, Harvard Medical School, Boston, Massachusetts.

3. 3Department of Social and Behavioral Sciences, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.

4. 4Duke Cancer Institute, Durham, North Carolina.

5. 5Memorial Sloan Kettering Cancer Center, New York, New York.

6. 6Dana-Farber Cancer Institute, Boston, Massachusetts.

7. 7Patient author, Durham, North Carolina.

8. 8Section of Hematology and Oncology, Tulane University School of Medicine, New Orleans, Louisiana.

9. 9University Hospitals Seidman Cancer Center, Cleveland, Ohio.

10. 10Division of Medical Oncology, University of Washington, Seattle, Washington.

11. 11Fred Hutchinson Cancer Center, Seattle, Washington.

12. 12University of Virginia Cancer Center, Charlottesville, Virginia.

13. 13Prostate Cancer Clinical Trials Consortium (PCCTC), New York, New York.

14. 14Karmanos Cancer Institute, Detroit, Michigan.

15. 15Department of Oncology, University of California San Diego Moores Cancer Center, La Jolla, California.

16. 16Cancer ABCs, Brooklyn, New York.

17. 17Division of Hematology and Medical Oncology, Weill Cornell Medical Center, New York, New York.

18. 18Department of Medicine, Division of Oncology, University of North Carolina School of Medicine, Chapel Hill, North Carolina.

19. 19Fox Chase Cancer Center, Philadelphia, Pennsylvania.

20. 20African-Caribbean Cancer Consortium, Philadelphia, Pennsylvania.

21. 21Mayo Clinic Comprehensive Cancer Center, Jacksonville, Florida.

22. 22Prostate Cancer Transatlantic Consortium (CaPTC), Jacksonville, Florida.

23. 23Convergent Therapeutics, Cambridge, Massachusetts.

24. 24Movember Foundation, Melbourne, Australia.

25. 25Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.

Abstract

Abstract Bone pain is a well-known quality-of-life detriment for individuals with prostate cancer and is associated with survival. This study expands previous work into racial differences in multiple patient-reported dimensions of pain and the association between baseline and longitudinal pain and mortality. This is a prospective cohort study of individuals with newly diagnosed advanced prostate cancer enrolled in the International Registry for Men with Advanced Prostate Cancer (IRONMAN) from 2017 to 2023 at U.S. sites. Differences in four pain scores at study enrollment by race were investigated. Cox proportional hazards models and joint longitudinal survival models were fit for each of the scale scores to estimate HRs and 95% confidence intervals (CI) for the association with all-cause mortality. The cohort included 879 individuals (20% self-identifying as Black) enrolled at 38 U.S. sites. Black participants had worse pain at baseline compared with White participants, most notably a higher average pain rating (mean 3.1 vs. 2.2 on a 10-point scale). For each pain scale, higher pain was associated with higher mortality after adjusting for measures of disease burden, particularly for severe bone pain compared with no pain (HR, 2.47; 95% CI: 1.44–4.22). The association between pain and all-cause mortality was stronger for participants with castration-resistant prostate cancer compared with those with metastatic hormone-sensitive prostate cancer and was similar among Black and White participants. Overall, Black participants reported worse pain than White participants, and more severe pain was associated with higher mortality independent of clinical covariates for all pain scales. Significance: Black participants with advanced prostate cancer reported worse pain than White participants, and more pain was associated with worse survival. More holistic clinical assessments of pain in this population are needed to determine the factors upon which to intervene to improve quality of life and survivorship, particularly for Black individuals.

Funder

HHS | NIH | National Cancer Institute

HHS | NIH | National Institute of General Medical Sciences

Publisher

American Association for Cancer Research (AACR)

Reference38 articles.

1. Estimating the number of men living with metastatic prostate cancer in the United States;Devasia;Cancer Epidemiol Biomarkers Prev,2023

2. Emerging categories of disease in advanced prostate cancer and their therapeutic implications;Aggarwal;Oncology,2017

3. Recognizing symptom burden in advanced prostate cancer: a global patient and caregiver survey;Drudge-Coates;Clin Genitourin Cancer,2018

4. Pain in castration-resistant prostate cancer with bone metastases: a qualitative study;Gater;Health Qual Life Outcomes,2011

5. Individual differences in the subjective experience of pain: new insights into mechanisms and models;Coghill;Headache,2010

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3